• N/A
    Market Cap
  • -72.04%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: N/A
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400%

The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.

10/07/2025, 4:09 PM • Benzinga

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.

09/03/2025, 7:30 AM • The Motley Fool

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Jyong Biotech presented Phase III clinical trial results for BOTRESO, a drug for benign prostatic hyperplasia, and Phase II results for MCS-8, a potential prostate cancer prevention drug, at the 22nd Urological Association of Asia Congress.

08/22/2025, 9:00 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$2.08
$2.38
$2.22
1-Year Range
$1.46
$65.62
$2.22
Latest Close$2.22
Change
+$0.17 (+7.66%)
Volume207,465
Shares Outstanding76.0M
P/E (TTM)-37.00
Diluted EPS (TTM)-$0.06

Information as of 07/02/2026

Company Profile

JYONG BIOTECH LTD
https://jyongbio.com
N/A
Market Cap
-$4.7M
Net Income
Sector: Healthcare
Industry: Biotechnology
No. 95, Xintai 5th Road, New Taipei City, Taiwan, 221
886 2 2732 5205

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Key Executives

  • Wei Zhang
  • Wanwen Su
  • Fu-Feng Kuo
  • Fenglin Hsu

Current Ownership Distribution

  • Other75.6M (99.39%)
  • Institutions453,640 (0.60%)
  • Mutual Funds8,476 (0.01%)
  • Insiders0 (0.00%)